ArticleBrain communications2020
11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 68 citations in OpenAlex.
- A randomized sequential cross-over trial evaluating five purportedly ICP-lowering drugs in idiopathic intracranial hypertension.Headache · 2025Trial
- The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.Brain : a journal of neurology · 2023Trial
- 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.Nature communications · 2023Trial
- Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension.European journal of endocrinology · 2022Trial
- Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia.The Journal of clinical endocrinology and metabolism · 2022Trial
- Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.Diabetes, obesity & metabolism · 2022Trial
- 11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.The Journal of clinical endocrinology and metabolism · 2021Trial
- Article
- Idiopathic Intracranial Hypertension Is Characterized by a Distinct Proteomic Profile.Annals of neurology · 2026Article
- Idiopathic Intracranial Hypertension: Updates on Pathophysiology and Diagnosis.Advances and technical standards in neurosurgery · 2026Review
- Context-dependent roles of 11β-HSD1 in bone and skeletal muscle diseases.American journal of translational research · 2026Review
- Routine Blood and Cerebrospinal Fluid Markers in Newly Diagnosed Idiopathic Intracranial Hypertension: An Exploratory Case-Control Study.Eye and brain · 2026Article
- Idiopathic Intracranial Hypertension in Children and Adolescents with Obesity: A Narrative Review.Children (Basel, Switzerland) · 2025Review
- Human Adipose Tissue 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Without Tachyphylaxis by Clofutriben, a Pseudo-Irreversible Enzyme Inhibitor.Clinical and translational science · 2025Article
- Infographic: landmark trials in Neuro-Ophthalmology-results of the phase II idiopathic intracranial hypertension drug trial.Eye (London, England) · 2025Article
- Current Understanding of the Pathophysiology of Idiopathic Intracranial Hypertension.Current neurology and neuroscience reports · 2025Review
- The Impact of Idiopathic Intracranial Hypertension on Cardiovascular Disease Risk Among UK Women: An Obesity-Adjusted Analysis.ASIDE internal medicine · 2025Article
- Covert cerebrospinal fluid dynamics dysfunction: evolution from conventional to innovative therapies.Frontiers in neurology · 2025Review
- Idiopathic intracranial hypertension: Imaging and clinical fundamentals.World journal of radiology · 2024Review
- Metabolic Dysfunction in Idiopathic Intracranial Hypertension: Current Theories and Updates.Aging and disease · 2024Review
Corrections and comments
- Erratum issuedCorrigendum.2020
Authors and funding
25 authors at 8 institutions in 1 country.
Keira MarkeyInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
James MitchellInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Hannah BotfieldInstitute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Ryan S OttridgeBirmingham Clinical Trials Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Tim MatthewsBirmingham Neuro-Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham B15 2WB, UK.
Anita KrishnanDepartment of Neurology, The Walton Centre NHS Foundation Trust, Liverpool L9 7LJ, UK.
Rebecca WoolleyBirmingham Clinical Trials Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Connar WestgateInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Andreas YiangouInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Zerin AlimajstorovicInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Pushkar ShahInstitute of Neurological Sciences, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow G51 4TF, UK.
Caroline RickNottingham Clinical Trials Unit, Queens Medical Centre, Nottingham NG7 2UH, UK.
Natalie IvesBirmingham Clinical Trials Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Angela E TaylorInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Lorna C GilliganInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Carl JenkinsonInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Wiebke ArltInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
William ScottonInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Rebecca J FaircloughEmerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0SL, UK.
Rishi SinghalUpper GI Unit and Minimally Invasive Unit, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham B9 5SS, UK.
Paul M StewartMedical School, University of Leeds, Leeds LS2 9JT, UK.
Jeremy W TomlinsonOxford Centre for Diabetes, Endocrinology & Metabolism (OCDEM), NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Headington, Oxford OX3 7LJ, UK.
Gareth G LaveryInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Susan P MollanInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Alexandra J SinclairInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.ORCID 0000-0001-9396-7330
University of Birmingham · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBAstraZeneca (United Kingdom) · GBChurchill Hospital · GBNHS Greater Glasgow and Clyde · GBQueen's Medical Centre · GBUniversity of Leeds · GBUniversity of Liverpool · GB
Funding
Medical Research Council MR/K015184/1Medical Research Council MR/N024591/1Medical Research Council MR/P011462/1Wellcome Trust
Abstract
Treatment options for idiopathic intracranial hypertension are limited. The enzyme 11β-hydroxysteroid dehydrogenase type 1 has been implicated in regulating cerebrospinal fluid secretion, and its activity is associated with alterations in intracranial pressure in idiopathic intracranial hypertension. We assessed therapeutic efficacy, safety and tolerability and investigated indicators of
Indexed as
11β-hydroxysteroid dehydrogenase type 1idiopathic intracranial hypertensionpapilloedemaphase IIrandomized controlled trial
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.